Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Behavioral EDC exposure reduction with semaglutide in obesity
ChiCTR2500114628Phase 3Completed
- Sponsor
- The First Affiliated Hospital of University of Science and Technology of China
- Start
- Jan 2026
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised trial of semaglutide in obesity and Overweight (2 arms), sponsored by The First Affiliated Hospital of University of Science and Technology of China. Primary endpoints: Weight change and Change in body fat percentage. Started Jan 2026; status: completed.
02
Drugs
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on ChiCTR2500114628.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500114628.